Janus Living

JAN · NYSE

$29.23+$0.59 (+2.06%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $28.64

JAN analyst rating

BuyConsensus of 14 analysts over the last 12 months. 86% rate it a buy.

Strong buy1
Buy11
Hold2
Underperform0
Sell0

12-month price target · 16 analysts

Average $35.85 (+22.6% upside)

Low: $31.31
Now: $29.23
High: $42.00

Upgrades and downgrades

The latest rating actions, newest first

JAN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Oct 19, 2026	Maintains	Overweight	$35.00 → $34.00	48%
Barclays	Oct 13, 2026	Maintains	Overweight	$34.00 → $33.00	38%
Scotiabank	Sep 17, 2026	Maintains	Sector Outperform	$31.00 → $33.00	47%
Compass Point	Sep 16, 2026	Initiates	Neutral	$37.00	14%
Jefferies	Sep 15, 2026	Initiates	Buy	$36.00	33%
Scotiabank	Sep 2, 2026	Maintains	Sector Outperform	$30.00 → $31.00	47%
Wells Fargo	Sep 1, 2026	Maintains	Overweight	$33.00 → $35.00	51%
Barclays	Aug 31, 2026	Maintains	Overweight	$33.00 → $34.00	38%
JP Morgan	Aug 18, 2026	Maintains	Overweight	$30.00 → $34.00	53%
Morgan Stanley	Aug 18, 2026	Maintains	Overweight	$28.00 → $31.00	56%

The case for and against

Updated Oct 18, 2026

Bull case

Janus Living is favorably positioned because it combines a pure-play, RIDEA-structured senior housing portfolio with strong industry fundamentals, allowing it to benefit directly from elevated SHOP trends and life plan community growth. Management has deployed about $1.1 billion of acquisitions since the IPO, expects another $500 million before year-end, and is targeting low-6.0% going-in cap rates that can improve to 7.5% or better by year 3, supporting roughly a ~10% 2-year SS NOI CAGR and stronger core earnings. Its deep liquidity of about $1.0 billion to $2.25 billion, no debt, and repeated equity raises at premiums to prior levels give it ample capacity to pursue accretive external growth and lift FFO toward $0.98 in 2026, $1.20 in 2027, and $1.43 in 2028.

Bear case

Janus Living is vulnerable to a weakening senior housing backdrop because the downside case assumes fundamentals plateau, life plan sales pull back, and the recently transitioned portfolio only delivers more average growth, which would cut 4Q27-3Q28 AFFO estimates by about 10%. The company also faces meaningful structural risks from elevated dependence on RIDEA operating performance, operator or tenant bankruptcy risk, interest-rate volatility, and potential healthcare reimbursement or regulatory changes, while an uptick in supply could pressure occupancy and pricing. With the stock already trading at 21x 2027E AFFO and a 43% premium to NAV, the valuation leaves limited room for disappointment if capital deployment becomes more cautious or macro conditions weaken.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.